Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session - Sarcoma

A phase II single arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classical Kaposi Sarcoma (CKS)

Date

22 Nov 2019

Session

Mini Oral session - Sarcoma

Topics

Immunotherapy

Tumour Site

Soft Tissue Sarcomas

Presenters

Alona Zer

Citation

Annals of Oncology (2019) 30 (suppl_9): ix135-ix139. 10.1093/annonc/mdz433

Authors

A. Zer1, O. Icht1, O. Jacobi1, E. Fenig1, S. Shamai2, O. Merimsky2, R. Shapira3, H. Bernstine4, R. Weitzen5, O. Vornikova6, E. Ben-Ami5, G. Bar-Sela6, S.M. Stemmer7, M. Lotem8

Author affiliations

  • 1 Medical Oncology, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, 4941492 - Petah Tikva/IL
  • 2 Medical Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv/IL
  • 3 Medical Oncology, Ella Institute for Immuno-Oncology and melanoma, Sheba medical center, Tel Aviv/IL
  • 4 Nuclear Medicine, Rabin Medical Center , Beilinson Campus, 4941492 - Petah Tikva/IL
  • 5 Medical Oncology, Chaim Sheba Medical Center, 52621 - Ramat Gan/IL
  • 6 Medical Oncology, HaEmek Medical Center, Afula/IL
  • 7 Oncology, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, 49100 - Petah Tikva/IL
  • 8 Oncology, Hadassah Ein Kerem, 91120 - Jerusalem/IL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.